<table border="single" id="id_01da04d1-608d-44b8-91e6-810513e4d37a" width="499" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="17.0%"></col>
<col width="16.2%"></col>
<col width="16.2%"></col>
<col width="6.2%"></col>
<col width="15.0%"></col>
<col width="14.4%"></col>
<col width="14.8%"></col>
<tbody>
<tr id="id_c64f69c9-8834-42e6-bc76-2dfcc9dd9fd8" stylecode="Toprule">
<td align="center" colspan="7" stylecode="Botrule" valign="middle">
<content stylecode="bold">Table 4 Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interaction trials were conducted in HIV-1 positive subjects) </content>
</td>
</tr>
<tr id="id_aab9106e-b087-4eff-9549-bd4fa5a25364">
<td align="center" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">Co-administered Drug </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">Dose of <br/>Co-administered Drug </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">Dose Regimen of<br/>Nevirapine </content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">n </content>
</td>
<td align="center" colspan="3" stylecode="Botrule" valign="middle">
<content stylecode="bold">% Change of Co-administered Drug<br/>Pharmacokinetic Parameters (90% CI)</content>
</td>
</tr>
<tr id="id_0a799039-9b15-491e-b17d-af7370744381">
<td align="center" colspan="3" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">Antiretrovirals</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="middle"></td>
<td align="center" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">AUC</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="middle">
<content stylecode="bold">Cmax</content>
</td>
<td align="center" stylecode="Botrule" valign="middle">
<content stylecode="bold">Cmin</content>
</td>
</tr>
<tr id="id_ba759cf9-f56b-42a5-99b9-7c576686fdee">
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">Atazanavir/ Ritonavira, d</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">300/100 mg QD day<br/>4 to 13, then 400/100 mg<br/>QD, day 14 to 23</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg BID day 1 to 23.<br/>Subjects were treated with nevirapine prior to trial entry.</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">
<br/>23</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>300/100 mg<br/>
</content>↓42<br/>(↓52 to ↓29)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>300/100 mg<br/>
</content>↓28<br/>(↓40 to ↓14)</td>
<td align="center" stylecode="Botrule" valign="top">
<content stylecode="underline">Atazanavir<br/>300/100 mg<br/>
</content>↓72<br/>(↓80 to ↓60)</td>
</tr>
<tr id="id_7f07a692-e95f-409d-9c95-b4c8299ffbb8">
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>400/100 mg<br/>
</content>↓19<br/>(↓35 to ↑2)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="underline">Atazanavir<br/>400/100 mg<br/>
</content>↑2<br/>(↓15 to ↑24)</td>
<td align="center" stylecode="Botrule" valign="top">
<content stylecode="underline">Atazanavir<br/>400/100 mg<br/>
</content>↓59<br/>(↓73 to ↓40)</td>
</tr>
<tr id="id_c069f955-29ef-4163-8b5f-7f8218a3b73c">
<td align="left" stylecode="Botrule Rrule" valign="top">Darunavir/ Ritonavire</td>
<td align="left" stylecode="Botrule Rrule" valign="top">400/100 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID</td>
<td align="center" stylecode="Botrule Rrule" valign="top">8</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑24<br/>(↓3 to ↑57)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑40<br/>(↑14 to ↑73)</td>
<td align="center" stylecode="Botrule" valign="top">↑2<br/>(↓21 to ↑32)</td>
</tr>
<tr id="id_b6062ded-47a9-4bdd-825c-2d99dc2bf594">
<td align="left" stylecode="Botrule Rrule" valign="top">Didanosine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">100 to 150 mg BID </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">18</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_94cfc072-3c22-4dd3-8f65-01f448d6e655">
<td align="left" stylecode="Botrule Rrule" valign="top">Efavirenza</td>
<td align="left" stylecode="Botrule Rrule" valign="top">600 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>400 mg QD x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">17</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓28<br/>(↓34 to ↓14)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓12<br/>(↓23 to ↑1)</td>
<td align="center" stylecode="Botrule" valign="top">↓32<br/>(↓35 to ↓19)</td>
</tr>
<tr id="id_9d1e8e0f-a38e-44f7-ab7e-2b9a64a29387">
<td align="left" stylecode="Botrule Rrule" valign="top">Fosamprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">1400 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID.<br/>Subjects were treated with<br/>nevirapine prior to trial entry.</td>
<td align="center" stylecode="Botrule Rrule" valign="top">17</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓33<br/>(↓45 to ↓20)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓25<br/>(↓37 to ↓10)</td>
<td align="center" stylecode="Botrule" valign="top">↓35<br/>(↓50 to ↓15)</td>
</tr>
<tr id="id_1135dd34-76c4-4c40-abd7-74128c69336e">
<td align="left" stylecode="Botrule Rrule" valign="top">Fosamprenavir/ Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">700/100 mg BID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID.<br/>Subjects were treated with<br/>nevirapine prior to trial entry</td>
<td align="center" stylecode="Botrule Rrule" valign="top">17</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓11<br/>(↓23 to ↑3)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">↓19<br/>(↓32 to ↓4)</td>
</tr>
<tr id="id_d57e8f35-7cce-4809-93d0-d36624ee0a1f">
<td align="left" stylecode="Botrule Rrule" valign="top">Indinavira </td>
<td align="left" stylecode="Botrule Rrule" valign="top">800 mg q 8 H </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">19</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓31<br/>(↓39 to ↓22)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓15<br/>(↓24 to ↓4)</td>
<td align="center" stylecode="Botrule" valign="top">↓44<br/>(↓53 to ↓33)</td>
</tr>
<tr id="id_0d31a315-4528-46e4-ae62-6e0e62e1ab2c">
<td align="left" stylecode="Botrule Rrule" valign="top">Lopinavira, b</td>
<td align="left" stylecode="Botrule Rrule" valign="top">300/75 mg/m2 <br/>(lopinavir/ ritonavir)b</td>
<td align="left" stylecode="Botrule Rrule" valign="top">7 mg/kg or 4 mg/kg <br/>QD x 2 weeks;<br/>BID x 1 week </td>
<td align="center" stylecode="Botrule Rrule" valign="top">12, 15c</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓22<br/>(↓44 to ↑9)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓14<br/>(↓36 to ↑16)</td>
<td align="center" stylecode="Botrule" valign="top">↓55<br/>(↓75 to ↓19)</td>
</tr>
<tr id="id_6bd92c17-670e-479b-8636-d1e3e50751fb">
<td align="left" stylecode="Botrule Rrule" valign="top">Lopinavira </td>
<td align="left" stylecode="Botrule Rrule" valign="top">400/100 mg BID<br/>(lopinavir/ ritonavir) </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID &gt;1 year</td>
<td align="center" stylecode="Botrule Rrule" valign="top">22, 19c</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓27<br/>(↓47 to ↓2)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓19<br/>(↓38 to ↑5)</td>
<td align="center" stylecode="Botrule" valign="top">↓51<br/>(↓72 to ↓26)</td>
</tr>
<tr id="id_8b74d033-9b15-43bb-ad7e-f859ce7e7830">
<td align="left" stylecode="Botrule Rrule" valign="top">Maravirocf</td>
<td align="left" stylecode="Botrule Rrule" valign="top">300 mg SD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg BID</td>
<td align="center" stylecode="Botrule Rrule" valign="top">8</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑1<br/>(↓35 to ↑55)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑54<br/>(↓6 to ↑151)</td>
<td align="center" stylecode="Botrule" valign="top">↔</td>
</tr>
<tr id="id_c1923b2d-8245-4b70-9c23-4fe5e2535c5e">
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">Nelfinavira <br/>Nelfinavir-M8 metabolite </td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">750 mg TID </td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days </td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">23</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">↓32<br/>(↓50 to ↑5)</td>
</tr>
<tr id="id_b3f61d7a-dab8-46d0-a543-7a1f50e18a4b">
<td align="center" stylecode="Botrule Rrule" valign="top">↓62<br/>(↓70 to ↓53)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓59<br/>(↓68 to ↓48)</td>
<td align="center" stylecode="Botrule" valign="top">↓66<br/>(↓74 to ↓55)</td>
</tr>
<tr id="id_2f7a3271-1eb0-4e0b-a683-2fa3667620f1">
<td align="left" stylecode="Botrule Rrule" valign="top">Ritonavir </td>
<td align="left" stylecode="Botrule Rrule" valign="top">600 mg BID </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">18</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">↔</td>
</tr>
<tr id="id_1562695f-ee4b-4f54-9072-e70a4a2b1826">
<td align="left" stylecode="Botrule Rrule" valign="top">Stavudine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">30 to 40 mg BID </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">22</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_44798bc3-d5f6-44ed-9865-d4ad640ec9d2">
<td align="left" stylecode="Botrule Rrule" valign="top">Zalcitabine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">0.125 to 0.25 mg TID </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days </td>
<td align="center" stylecode="Botrule Rrule" valign="top">6</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_433f1bc3-7c97-4af0-8b91-41c90ab16624">
<td align="left" stylecode="Botrule Rrule" valign="top">Zidovudine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">100 to 200 mg TID</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">11</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓28<br/>(↓40 to ↓4)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓30<br/>(↓51 to ↑14)</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_0822bdfd-001f-4168-85de-f1af1e9040dd">
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Other Medications </content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">AUC</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Cmax</content>
</td>
<td align="center" stylecode="Botrule" valign="top">
<content stylecode="bold">Cmin</content>
</td>
</tr>
<tr id="id_bad7f7b2-850a-4df4-b2cc-15d80361498d">
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">Clarithromycina<br/>Metabolite<br/>14-OH-clarithromycin </td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">500 mg BID</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">15</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓31<br/>(↓38 to ↓24)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓23<br/>(↓31 to ↓14)</td>
<td align="center" stylecode="Botrule" valign="top">↓56<br/>(↓70 to ↓36)</td>
</tr>
<tr id="id_3d50a837-e146-41cf-bc17-d0bb2698d9ca">
<td align="center" stylecode="Botrule Rrule" valign="top">↑42<br/>(↑16 to ↑73)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑47<br/>(↑21 to ↑80)</td>
<td align="center" stylecode="Botrule" valign="top">↔</td>
</tr>
<tr id="id_d18f2d7b-2623-46d6-a106-18cecf56e93f">
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">Ethinyl estradiola and <br/>Norethindronea</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">0.035 mg<br/>(as Ortho-Novum® 1/35) <br/>1 mg<br/>(as Ortho-Novum® 1/35)</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">10</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓20<br/>(↓33 to ↓3)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_da1527d4-967e-4b8c-bed9-b26e9ce84309">
<td align="center" stylecode="Botrule Rrule" valign="top">↓19<br/>(↓30 to ↓7)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓16<br/>(↓27 to ↓3)</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_2d1b2361-1e28-4f77-bf38-f44de353f51a">
<td align="left" stylecode="Botrule Rrule" valign="top">Depomedroxy-<br/>progesterone acetate</td>
<td align="left" stylecode="Botrule Rrule" valign="top">150 mg every 3 months</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">32</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">↔</td>
</tr>
<tr id="id_9a65feae-5fa9-453b-81ef-2ecbfc446b20">
<td align="left" stylecode="Botrule Rrule" valign="top">Fluconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">19</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">↔</td>
</tr>
<tr id="id_ca52a801-d38f-4a9b-b109-cd2bd8f07e47">
<td align="left" stylecode="Botrule Rrule" valign="top">Ketoconazolea </td>
<td align="left" stylecode="Botrule Rrule" valign="top">400 mg QD </td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">21</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓72<br/>(↓80 to ↓60)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↓44<br/>(↓58 to ↓27)</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_fa071397-fe22-493a-91f7-eefb37ffd331">
<td align="left" stylecode="Botrule Rrule" valign="top">Methadonea</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Individual Subject Dosing</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID ≥7 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">9</td>
<td align="left" colspan="3" stylecode="Botrule" valign="top">In a controlled pharmacokinetic trial with<br/>9 subjects receiving chronic methadone to <br/>whom steady-state nevirapine therapy was<br/>added, the clearance of methadone was <br/>increased by 3-fold, resulting in symptoms <br/>of withdrawal, requiring dose adjustments <br/>in 10 mg segments, in 7 of the 9 subjects. <br/>Methadone did not have any effect on <br/>nevirapine clearance.</td>
</tr>
<tr id="id_b6a885de-89a2-42b7-9b15-ef1d0dae5b85">
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">Rifabutina <br/>Metabolite<br/>25-O-desacetyl-rifabutin </td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">150 or 300 mg QD</td>
<td align="left" rowspan="2" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" rowspan="2" stylecode="Botrule Rrule" valign="top">19</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑17<br/>(↓2 to ↑40)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑28<br/>(↑9 to ↑51)</td>
<td align="center" stylecode="Botrule" valign="top">↔</td>
</tr>
<tr id="id_2b923267-31ef-4427-ac1d-3e3cc8a5fa66">
<td align="center" stylecode="Botrule Rrule" valign="top">↑24<br/>(↓16 to ↑84)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑29<br/>(↓2 to ↑68)</td>
<td align="center" stylecode="Botrule" valign="top">↑22<br/>(↓14 to ↑74)</td>
</tr>
<tr id="id_8fe16dbc-39fb-4d95-b68b-6e00597201bb">
<td align="left" stylecode="Botrule Rrule" valign="top">Rifampina</td>
<td align="left" stylecode="Botrule Rrule" valign="top">600 mg QD</td>
<td align="left" stylecode="Botrule Rrule" valign="top">200 mg QD x 14 days;<br/>200 mg BID x 14 days</td>
<td align="center" stylecode="Botrule Rrule" valign="top">14</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↑11<br/>(↓4 to ↑28)</td>
<td align="center" stylecode="Botrule Rrule" valign="top">↔</td>
<td align="center" stylecode="Botrule" valign="top">§</td>
</tr>
<tr id="id_8dfe7599-fcef-4ec0-98e4-0bc2354ffa90">
<td align="left" colspan="7" stylecode="Lrule Botrule" valign="top">
<paragraph>§ = Cmin below detectable level of the assay<br/>↑ = Increase, ↓<content stylecode="italics">= </content>Decrease, ↔ = No Effect<br/>a For information regarding clinical recommendations, see <content stylecode="italics">
<linkhtml href="http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5f6c3eed-2a5d-46ed-9a7c-59715f338a15">Drug Interactions (7)</linkhtml>.<br/>
</content>b Pediatric subjects ranging in age from 6 months to 12 years.<br/>c Parallel group design; n for nevirapine+lopinavir/ritonavir, n for lopinavir/ritonavir alone.<br/>d Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir<br/>PK are relative to atazanavir/ritonavir 300/100 mg alone. <br/>e Based on between-trial comparison. <br/>f Based on historical controls</paragraph>
</td>
</tr>
</tbody>
</table>